News | February 18, 2022
AptarGroup reported 2021 sales at US $3.23 billion
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Subscribe To Our Newsletter & Stay Updated
